For 2017 to work, Biogen needs a successful commercial launch of Spinraza, the newly approved treatment for spinal muscular atrophy, a rare and fatal disease that strikes kids. Biogen said Thursday that it expects no revenue growth in 2017 compared to last year, at best.
Category: Hemophilia
Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales
Years before becoming a top cancer specialist, Eric Winer used to save money on his own medical care by talking U.S. pharmacists into giving him expired treatments for free. Winer, who has a bleeding disorder known as hemophilia, knew the drugs would still work for a brief time after the official use-by date.